clinical trial · NCT06538272
Study to Investigate the Chemotherapy-Induced Peripheral Neuropathy (CIPN) Onset-Suppressing Effect and Safety of ONO-2910 in Patients With Breast Cancer Receiving Weekly Paclitaxel
Ono Pharmaceutical Co., Ltd.·phase2·completed·n = 210
CIPN - Chemotherapy-Induced Peripheral NeuropathyONO-2910Placebo
brief summary
To investigate the safety and CIPN onset-suppressing effect of ONO-2910 in participants receiving paclitaxel (PTX) weekly as chemotherapy for breast cancer in Japan.
started
Aug 31, 2023
primary completion
Sep 19, 2024
completion
Sep 19, 2024
last updated
Apr 3, 2025
official title
An Early Phase II, Multicenter, Placebo-Controlled, Randomized, Double-Blind, Parallel-Group, Comparison Study to Investigate the Chemotherapy-Induced Peripheral Neuropathy (CIPN) Onset-Suppressing Effect and Safety of ONO-2910 in Patients With Breast Cancer Receiving Weekly Paclitaxel
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol